USX:BBIO - BridgeBio Pharma Inc BRIDGEBIO PHARMA INC
Sector: Health Care, Industry: Biotechnology
Next Earnings: 23 Feb 2022
Add to Watchlist
   
Add Alert 


Yahoo Finance

USD 47.98    -1.370 (-2.78%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

15 Oct 2021


Loading...
Loading...
Loading...

General

CEO: Dr. Neil Kumar Ph.D.

IPO: 2019-06-27

Headquarters: US

Employees: 385

Homepage

Description

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.